Havrdova E, et al. Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients With Relapsing Multiple Sclerosis in the OPERA I and OPERA II Trials. EAN 2017, PR1092.
Solanezumab bij preklinische ziekte van Alzheimer: fase III-resultaten
okt 2023 | Dementie